|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.9320 - 0.9748|
|52 Week Range||0.7800 - 4.7800|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||3.59|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Canopy Rivers Inc. ("Canopy Rivers") (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, portfolio companies made several announcements that demonstrate the portfolio's continued growth heading into 2020. Among others, this includes new features from a business intelligence and analytics software platform, a licensed producer responding to consumer demands for high-THC products with the launch of four new cannabis strains, and a portfolio company expanding its retail footprint. A summary of key developments includes the following:
Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) has added Thirty Five Ventures to its advisory board. Thirty Five Ventures is owned by two-time National Basketball Association champion Kevin Durant of the Brooklyn Nets and sports exec Rich Kleiman. The advisory board includes John Ruffolo of the Canadian Council of Innovators and OMERS Ventures and Meg Lovell, former co-head of M&A for Imperial Tobacco Group plc (OTC: IMBBY).
TORONTO, Nov. 21, 2019 /PRNewswire/ - Canopy Rivers Inc. ("Canopy Rivers") (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, portfolio companies continued broadening their operations as they aim for success in the growing market. For one company, this meant introducing more tools to help cannabis retailers understand consumers, while another agreed to expand its distribution network by leveraging Canopy Rivers' strategic alliance with Kindred Partners Inc. ("Kindred"). Headset, Inc. ("Headset") launched Retail Market Benchmark for Headset Retailer, its retail data intelligence tool.
Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF ) posted a second-quarter net loss of CA$4.41 million ($3.3 million) Thursday, down from net income of CA$10.95 million in the same period last year. The cannabis ...
TORONTO , Nov. 14, 2019 /PRNewswire/ - Canopy Rivers Inc. (the " Company " or " Canopy Rivers ") (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, today released ...
Three months in the cannabis industry is a long time. And, especially in the last three months, it feels as though the market has shifted dramatically. But what has this meant for venture capital? Canopy ...
Cannabis-focused venture capital firm Canopy Rivers Inc. (TSX:RIV) OTC: CNPOF ) said Thursday its portfolio company Radicle Medical Marijuana Inc. has obtained Health Canada’s approval for oil sales. With ...
TORONTO, Oct. 24, 2019 /PRNewswire/ - Canopy Rivers Inc. ("Canopy Rivers") (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, today announced that its portfolio company Radicle Medical Marijuana Inc. ("Radicle") has received approval for oil sales from Health Canada. This additional licence allows for the development and sale of new cannabis products, including cannabis oil and concentrates. This opens the door for Radicle's medical patients to access other product forms in the company's craft cannabis selection.
TerrAscend Corp. (CSE: TER) (OTC: TRSSF ) said Wednesday it has entered into a strategic collaboration with Kindred Partners Inc., a cannabis brokerage and services company. Kindred will provide brokerage ...
TORONTO , Oct. 21, 2019 /CNW/ - Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, will report its second quarter fiscal year 2020 financial results before markets open on Thursday, November 14, 2019 . Certain preliminary financial information pertaining to the Company may also be found in the financial results released by Canopy Growth Corporation (TSX: WEED, NYSE: CGC), which are currently scheduled to be released on November 14, 2019 .
James E. Wagner Cultivation (TSXV: JWCA) (OTCQX: JWCAF), a portfolio company of Canopy Rivers (TSX: RIV) (OTC: CNPOF), has been granted approval by Health Canada to increase cannabis production at its facility in Kitchener, Ontario. The approval allows the company to start the production in four new flowering rooms at its facility in Kitchener. The additional […]The post Canopy Rivers Gets Approval to Boost Cannabis Production appeared first on Market Exclusive.
TORONTO, Oct. 15, 2019 /PRNewswire/ - Canopy Rivers ("Canopy Rivers") (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, today announced that its portfolio company James E. Wagner Cultivation Corporation ("JWC") (TSXV: JWCA, OTCQX: JWCAF) received a Health Canada licence amendment allowing for cannabis production in four new flowering rooms at its flagship facility in Kitchener, Ontario. "We believe that this licence amendment demonstrates Health Canada's recognition of JWC, the quality of its operations, and its disciplined approach to expansion," said Olivier Dufourmantelle, Chief Operating Officer, Canopy Rivers. "Through its supply agreement with TerrAscend, JWC has an active role in the Canopy Rivers ecosystem.
TORONTO, Oct. 7, 2019 /PRNewswire/ - Canopy Rivers Inc. (the "Canopy Rivers") (TSX: RIV, OTC: CNPOF) today announced that its portfolio company, TerrAscend Corp. ("TerrAscend") (CSE: TER, OTCQX: TRSSF) has received approval from Health Canada for a significant expansion at its Mississauga, Ontario facility. TerrAscend expects that this milestone will help the company meet the increased consumer demand for premium cannabis products and brands coming with the next wave of Canadian cannabis legalization. As the first and only cannabis company with sales in Canada, the U.S., and Europe, TerrAscend has also earmarked the additional capacity to further serve the global markets where it operates.